Page 45 - Query Get News Today

CMS has proposed a National Coverage Determination decision memorandum specifying “coverage with evidence development” for FDA-approved monoclonal antibodies targeting amyloid for treating Alzheimer’s disease.This means Medicare would cover FDA-approved drugs in this class only for individuals who are enrolled in qualifying clinical trials, according to a CMS press release.

A new sleep research plan from the NIH aims to ensure that everyone gets a good night’s sleep and reduce the economic impact of sleep-related disorders. According to the NIH, 30% to 40% of adults in the U.S. and 65% to 80% of teenagers report experiencing a sleep problem, such as insufficient sleep, irregular timing of sleep and poor quality of sleep. Data cited by NIH indicate that the

Obstructive sleep apnea and COPD overlap syndrome is common and is associated with worse outcomes, poorer quality of life and a higher prevalence of comorbidities such as diabetes and hypertension compared with COPD only, researchers reported.“Our study suggests that OSA is common in patients with COPD in pulmonary outpatient clinics, and pulmonologists should ... consider screening for OSA

The FDA lifted its clinical hold on a series of trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.Allogene announced the hold in October 2021 based on the report of one patient with pretreated stage IV follicular lymphoma who showed evidence of a chromosomal abnormality after receiving the

Ketamine and mindfulness training may be effective as adjunctive treatments for patients with alcohol use disorder, according to a double-blind, placebo-controlled phase 2 clinical trial published in the American Journal of Psychiatry.“Depressive symptoms are common in individuals entering treatment for AUD, and the likelihood of alcohol relapse is elevated in patients with such symptoms.

In a new analysis of the REDUCE-IT trial, the treatment effect of icosapent ethyl was consistent across different agents and categories of statins patients were taking. As Healio previously reported, in the main results of REDUCE-IT, icosapent ethyl (Vascepa, Amarin), a pharmaceutical-grade omega-3 fatty acid, reduced risk for ischemic events compared with placebo in patients with elevated

Regenxbio has initiated a second phase 3 pivotal trial investigating RGX-314 in patients with wet age-related macular degeneration, according to a press release.

The FDA granted approval to Quviviq to treat adults with insomnia.Quviviq (daridorexant, Idorsia) is a dual orexin receptor antagonist that blocks the binding of wake-promoting neuropeptides orexins and is thought to minimize overactive wakefulness, as opposed to sedative treatments.

A patient survey indicated that forgetfulness was one of the top barriers to adherence to mupirocin and chlorhexidine gluconate bathing — both prescribed to prevent surgical site infections following total joint arthroplasty. “In our previous research, we found it was hard to look in the medical record data and really know if patients were using the products that were sent home, so we

Cutaneous adverse events appeared largely reversible and rarely led to therapy discontinuation among patients with metastatic melanoma treated with combination checkpoint inhibitors, according to a study in Cancer.Additionally, patients who experienced cutaneous toxicities after treatment with a combination of anti-CTLA-4 and anti-PD-1 therapy had a longer time to next treatment, suggesting a